Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Autoimmune diseases

- PMLiVE

Bristol Myers Squibb and Repertoire enter autoimmune disease partnership worth over $1.8bn

It is estimated that up to 50 million people in the US have an autoimmune disease

- PMLiVE

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

The company will gain rights to Alpine’s lead molecule, povetacicept, to treat IgA nephropathy

- PMLiVE

BMS and Shine Cancer Support’s UK research reveals disparities in cancer diagnosis

The Cancer Equals campaign and 1,000 Voices, Not 1 report aim to help address reasons for diagnostic delays

- PMLiVE

BMS and 2seventy’s multiple myeloma therapy Abecma receives expanded FDA approval

More than 35,700 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes

The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia

- PMLiVE

Bristol Myers Squibb shares positive phase 3 results for Krazati in non-small cell lung cancer

KRAS G12C occurs in approximately 14% of NSCLC, the most common form of lung cancer

- PMLiVE

AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

- PMLiVE

AstraZeneca’s Ultomiris receives FDA approval to treat rare autoimmune disease NMOSD

Neuromyelitis optica spectrum disorder is estimated to affect approximately 6,000 adults in the US

- PMLiVE

Bristol Myers Squibb shares positive results for Opdivo combination in advanced liver cancer

HCC is the most common primary liver cancer, accounting for 90% of all cases of liver cancer

- PMLiVE

Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma

Approximately 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Bristol Myers Squibb’s Opdivo combination receives FDA approval for urothelial carcinoma

More than 83,000 news cases of bladder cancer are expected to be diagnosed in the US this year

- PMLiVE

MHRA approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links